CINECA IRIS Institutional Research Information System

GABBIANI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.092
AS - Asia 4.127
EU - Europa 3.842
SA - Sud America 599
AF - Africa 225
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 19.902
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.826
IT - Italia 1.510
SG - Singapore 1.397
CN - Cina 1.255
SE - Svezia 772
HK - Hong Kong 622
BR - Brasile 497
BG - Bulgaria 324
DE - Germania 277
VN - Vietnam 232
CA - Canada 224
KR - Corea 189
RU - Federazione Russa 168
TR - Turchia 154
UA - Ucraina 152
GB - Regno Unito 142
FI - Finlandia 134
SN - Senegal 114
CH - Svizzera 86
IN - India 74
CI - Costa d'Avorio 61
FR - Francia 47
AT - Austria 45
JP - Giappone 44
BD - Bangladesh 38
EE - Estonia 33
PL - Polonia 28
IQ - Iraq 25
AR - Argentina 24
EC - Ecuador 22
ES - Italia 20
BE - Belgio 18
MX - Messico 18
NL - Olanda 18
VE - Venezuela 17
PK - Pakistan 16
GR - Grecia 15
SA - Arabia Saudita 14
ZA - Sudafrica 14
IE - Irlanda 11
MA - Marocco 9
UY - Uruguay 9
AU - Australia 8
LT - Lituania 8
CO - Colombia 7
CZ - Repubblica Ceca 7
MY - Malesia 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
AL - Albania 6
CL - Cile 6
ID - Indonesia 6
JO - Giordania 6
KE - Kenya 6
KZ - Kazakistan 6
BJ - Benin 5
BO - Bolivia 5
JM - Giamaica 5
OM - Oman 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
IR - Iran 4
NZ - Nuova Zelanda 4
PA - Panama 4
RS - Serbia 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AZ - Azerbaigian 3
BY - Bielorussia 3
EG - Egitto 3
NG - Nigeria 3
NO - Norvegia 3
PE - Perù 3
PH - Filippine 3
RO - Romania 3
HU - Ungheria 2
IL - Israele 2
KW - Kuwait 2
LI - Liechtenstein 2
SR - Suriname 2
UG - Uganda 2
XK - ???statistics.table.value.countryCode.XK??? 2
BH - Bahrain 1
BS - Bahamas 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HN - Honduras 1
KG - Kirghizistan 1
LB - Libano 1
LY - Libia 1
ME - Montenegro 1
MK - Macedonia 1
Totale 19.893
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.615
Fairfield 1.142
Ashburn 1.089
Houston 938
Ann Arbor 925
Singapore 685
Hong Kong 619
Santa Clara 609
Milan 513
Seattle 483
Chandler 464
Cambridge 409
Wilmington 377
Sofia 324
Serra 287
Shanghai 284
Dallas 273
Jacksonville 252
Hefei 237
Beijing 221
New York 195
Seoul 187
Ottawa 183
Boardman 143
Princeton 136
Nanjing 130
Los Angeles 123
Lawrence 115
Dakar 114
Medford 114
Izmir 96
Bern 85
Livorno 81
Abidjan 61
Jüchen 61
Dearborn 55
Buffalo 53
Rome 53
San Diego 53
Florence 52
São Paulo 48
Des Moines 47
Dong Ket 46
Munich 45
Istanbul 42
Redondo Beach 42
Pisa 41
Nanchang 40
Boulder 39
Tokyo 37
Vienna 37
Tallinn 33
Ho Chi Minh City 31
London 29
Fuzhou 26
Ogden 25
Hebei 23
Shenyang 22
Falls Church 21
Changsha 20
Bremen 19
Redwood City 19
Brussels 18
Frankfurt am Main 18
Kunming 18
Warsaw 17
Helsinki 16
Pune 16
San Jose 15
Belo Horizonte 14
Chicago 14
Hanoi 13
Jiaxing 13
Norwalk 13
Tianjin 13
Council Bluffs 12
Nuremberg 12
Prato 12
Quanzhou 12
Turku 12
Baghdad 11
Brasília 11
Padova 11
Rio de Janeiro 11
San Giuliano Terme 11
Toronto 11
Vicopisano 11
Brooklyn 10
Dhaka 10
Quito 10
Trento 10
Chennai 9
Guangzhou 9
Hangzhou 9
Kent 9
Montreal 9
Phoenix 9
Wuhan 9
Amsterdam 8
Betim 8
Totale 15.022
Salva come PNG Salva come JPEG
Nome #
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 281
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen 235
Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities 235
Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: The binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin 232
X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins 220
Photocytotoxic Pt(iv) complexes as prospective anticancer agents 211
The reaction of artemisinins with hemoglobin: A unified picture 206
Gold(III) Compounds as anticancer drugs 204
ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes 200
Peculiar Mechanistic and Structural Features of the Carboplatin-Cytochrome c System Revealed by ESI MS analysis 196
The C2 variant of human serum transferrin retains the iron binding properties of the native protein 193
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation 193
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells 192
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 191
Interaction of gold N-heterocyclic carbenes with nucleic acids 191
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c 189
Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands 189
Unravelling the Chemical Nature of Copper Cuprizone 188
Arene Ruthenium Complexes with Ethacrynic Acid-Modified Ligands: Synthesis, Characterization and Antiproliferative Activity 188
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs 187
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study 182
Interaction of a Gold(I) Dicarbene Anticancer Drug with Human Telomeric DNA G-Quadruplex: Solution and Computationally Aided X-ray Diffraction Analysis 182
Antitumor gold(III) complexes 180
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound 180
PtI2(DACH), the Iodido Analogue of Oxaliplatin as a Candidate for Colorectal Cancer Treatment: Chemical and Biological Features 180
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme 179
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles 178
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications 177
Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds 176
Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) 176
cis-Pt I2(NH3)2: a reappraisal 175
Solution chemistry and cytotoxic properties of novel organogold(III) compounds 174
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 173
Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity 173
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif 173
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 172
Metal-based compounds as prospective antileishmanial agents: Inhibition of Trypanothione reductase by selected gold complexes 171
DOTAP/DOPE and DC-Chol/DOPE Lipoplexes for Gene Delivery studied by Circular Dichroism and Biophysical Techniques 170
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 170
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study 170
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones 169
Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs 168
Metal compounds as inhibitors of B-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer’s disease 168
Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic Acid-Modified Ligands 168
Solution Behaviour and Biomolecular Interactions of Two Cytotoxic trans-Platinum(II) Complexes Bearing Aliphatic Amine Ligands 167
The copper(II) binding properties of the cyclic peptide c(HGHK) 166
Nanoparticles of Mg(OH)2: Synthesis and Application to Paper Conservation 166
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound 166
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme 166
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 166
Anticancer gold N-Heterocyclic carbene complexes: a comparative in vitro and ex vivo study 165
Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials 163
Structure-Function Relationships within Keppler-Type Antitumor Ruthenium(III) Complexes: the Case of 2-Aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)] 161
An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies 160
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis 160
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 157
The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model 156
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study 156
Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent 154
Chemical Modification of Auranofin Yields a New Family of Anticancer Drug Candidates: The Gold(I) Phosphite Analogues 150
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. 150
Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action 150
Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays 149
Novel platinum(II) compounds with O,S bidentate ligands: Synthesis, characterization, antiproliferative properties and biomolecular interactions 149
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro 149
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds 148
The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins 147
Ruthenium arene complexes with triphenylphosphane ligands: Cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution 147
New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro 147
Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. 146
Cytotoxic Ag(I) and Au(I) NHC-carbenes bind DNA and show TrxR inhibition 146
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives 145
Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: A joint mass spectrometry and circular dichroism investigation 145
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 145
Biophysical Characterization of Adducts Formed between Anticancer Metallodrugs and Selected Proteins: New Insights from X-ray Diffraction and Mass Spectrometry Studies 144
Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. 144
The mode of action of anticancer gold-based drugs: A structural perspective 144
Reactivity and Biological Properties of a Series of Cytotoxic PtI(2)(amine)(2) Complexes, Either cis or trans Configured 144
A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes 144
Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins 143
124I Radiolabeling of a AuIII-NHC Complex for In Vivo Biodistribution Studies 143
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c 142
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents 141
Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial "hot spots" for protein-protein recognition 141
Triethylphosphine gold iodide (I), the iodido analogue of Auranofin: comparative studies of a potential antineoplastic agent 140
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 140
New insights into the molecular mechanisms of selected anticancer metal compounds through bioinformatic analysis of proteomic data 139
Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties 139
Proteomic analysis of the cytotoxic effects induced by the organogold(iii) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 138
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation 138
Trans-cis-cis-[RuCl(2)(DMSO)(2)(2-amino-5-methyl-thiazole)(2)], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B 137
Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex 137
Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity 137
Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH3)3(phterpy)] Complex 137
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 135
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc 134
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 134
Synthesis, characterization and DNA interactions of [Pt3(TPymT)Cl3], the trinuclear platinum(II) complex of the TPymT ligand 134
Thermodynamic Evaluation of the Interactions between Anticancer Pt(II) Complexes and Model Proteins 133
Recent progress in the application of analytical techniques to anticancer metallodrug proteomics 131
Totale 16.560
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.206
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.206
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.008 0 0 0 0 0 0 79 316 188 164 69 192
2021/20221.554 17 90 169 129 267 168 62 90 62 13 141 346
2022/20231.858 274 218 133 139 147 239 47 155 375 25 79 27
2023/20241.722 247 208 294 127 283 282 56 32 27 20 46 100
2024/20254.034 5 136 25 252 400 392 405 170 377 526 497 849
2025/20262.302 246 579 427 313 322 411 4 0 0 0 0 0
Totale 20.229